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Eight MOR (µ-opioid receptor) peptides, six agonists and two antagonists, are comparatively 
evaluated in the mouse model for brain influx (multiple time regression and capillary depletion), brain 
efflux and metabolic stability in brain tissue as well as in plasma [1].  
 
 
 
 
 
 
 
 
 
Figure 1. Blood Brain Barrier (left) and investigated MOR peptides (right) 
Using these four individual responses di, a global desirability function D was created as follows: 
, where pi is a weighing factor attributed to the individual responses. Dermorphin yielded 
the highest D-value, indicating this peptide possessed the highest drugability characteristics compared 
to the other investigated peptides. In-vivo medical imaging confirmed the above D-based conclusions, 
and allowed a refinement of the weighing factors pi.  
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